MONMOUTH JUNCTION, N.J.,
Sept. 8, 2021 /PRNewswire/
-- CytoSorbents Corporation (NASDAQ: CTSO), a leader in
the treatment of life-threatening conditions in intensive care and
cardiac surgery using blood purification via its proprietary
polymer adsorption technology, announces a special Company
webinar highlighting the topline results of CytoSorbents'
U.S. CTC Multicenter Registry that demonstrate high survival using
CytoSorb® in Critically Ill COVID-19 patients on ECMO, on
Monday, September 13, 2021, at
5:00 p.m. EDT.
CytoSorbents Announces Webinar on Topline Results from U.S. CTC
Registry using CytoSorb® in COVID-19 Patients on ECMO
The CTC Registry included 52 consecutive critically ill COVID-19
patients with refractory acute respiratory distress syndrome (ARDS)
on life support with ECMO and CytoSorb, enrolled at five U.S.
medical centers under FDA Emergency Use Authorization. The
prerecorded presentation, geared towards clinicians, will be hosted
by Dr. Phillip Chan, CytoSorbents'
CEO and feature an overview of CytoSorb and its application in ECMO
by Dr. Chan, a review of the CTC Registry results by Dr. J. W.
Awori Hayanga, Professor of Cardiovascular and Thoracic Surgery at
the West Virginia University School of
Medicine and one of the contributing Site Principal Investigators
in the registry, followed by a short question and answer
session. The webinar will be available for viewing at any
time afterwards with registration.
Date: Monday, September 13, 2021
Time: 5:00 p.m. Eastern
Registration
Link: https://cyto.news/webinar-CTC-Registry
About CytoSorbents Corporation (NASDAQ:
CTSO)
CytoSorbents Corporation is a leader in the treatment of
life-threatening conditions in intensive care and cardiac surgery
using blood purification. Its flagship product, CytoSorb®, is
approved in the European Union with distribution in 68 countries
around the world as an extracorporeal cytokine adsorber designed to
reduce the "cytokine storm" or "cytokine release syndrome" seen in
common critical illnesses that may result in massive inflammation,
organ failure and patient death. These are conditions where
the risk of death can be extremely high, yet few to no effective
treatments exist. CytoSorb is also being used during and
after cardiothoracic surgery to remove inflammatory mediators that
can lead to post-operative complications, including multiple organ
failure. More than 143,000 CytoSorb devices have been
delivered to date. CytoSorb was originally introduced into
the European Union under CE-Mark as a first-in-kind cytokine
adsorber. Additional CE-Mark label expansions were received
for the removal of bilirubin and myoglobin in clinical conditions
such as liver disease and trauma, respectively, and both ticagrelor
and rivaroxaban during cardiothoracic surgery. The
DrugSorb-ATR™ Antithrombotic Removal System, which is based on the
same polymer technology as CytoSorb, has also been granted FDA
Breakthrough Designation for the removal of ticagrelor, as well as
FDA Breakthrough Designation for the removal of the direct oral
anticoagulant (DOAC) drugs rivaroxaban and apixaban in a
cardiopulmonary bypass circuit during urgent cardiothoracic
surgery.
CytoSorb has been granted U.S. FDA Emergency Use Authorization
in the COVID-19 pandemic as an extracorporeal cytokine
adsorber for use in adult, critically ill COVID-19 patients with
imminent or confirmed respiratory failure. The CytoSorb
device has neither been cleared nor approved for the indication to
treat patients with COVID-19 infection. The CytoSorb device
is authorized only for the duration of the declaration that
circumstances exist justifying the authorization of the emergency
use of the CytoSorb device under Section 564(b)(l) of the Act, 21
U.S.C § 360bbb-3(b)(1), unless the authorization is terminated or
revoked sooner.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received
non-dilutive grant, contract, and other funding of more than
$39.5 million from DARPA, the U.S.
Department of Health and Human Services (HHS), the National
Institutes of Health (NIH), National Heart, Lung, and Blood
Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special
Operations Command (SOCOM), Air Force Material Command (USAF/AFMC),
and others. The Company has numerous marketed products and
products under development based upon this unique blood
purification technology protected by many issued U.S. and
international patents and registered trademarks, and multiple
patent applications pending, including ECOS-300CY®, CytoSorb-XL™,
HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™,
DrugSorb™, DrugSorb-ATR™, ContrastSorb, and others. For
more information, please visit the Company's websites at
www.cytosorbents.com and www.cytosorb.com or follow us on Facebook
and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, anticipated future results
and performance, representations and contentions and are not
historical facts and typically are identified by use of terms such
as "may," "should," "could," "expect," "plan," "anticipate,"
"believe," "estimate," "predict," "potential," "continue" and
similar words, although some forward-looking statements are
expressed differently. You should be aware that the
forward-looking statements in this press release represent
management's current judgment and expectations, but our actual
results, events and performance could differ materially from those
in the forward-looking statements. Factors which could cause or
contribute to such differences include, but are not limited to, the
risks discussed in our Annual Report on Form 10-K, filed with the
SEC on March 9, 2021, as updated by
the risks reported in our Quarterly Reports on Form 10-Q, and in
the press releases and other communications to shareholders issued
by us from time to time which attempt to advise interested parties
of the risks and factors which may affect our business. We
caution you not to place undue reliance upon any such
forward-looking statements. We undertake no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise, other
than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
Investor Relations Contact:
Terri Anne Powers
Vice President, Investor Relations
and Corporate Communications
(732) 482-9984
tpowers@cytosorbents.com
U.S. Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
ekim@rubensteinpr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cytosorbents-announces-webinar-discussing-topline-results-from-the-us-ctc-registry-using-cytosorb-in-critically-ill-covid-19-patients-on-extracorporeal-membrane-oxygenation-ecmo-301371747.html
SOURCE CytoSorbents Corporation